JRJon Jarløv Rasmussen

Jon Jarløv Rasmussen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jon Jarløv Rasmussen has a total of 122 co-authors. Here are the top co-authors by number of shared publications:

  • Caroline Kistorp

    Department of Nephrology and Endocrinology, Copenhagen University Hospital Rigshospitalet , 2100 Copenhagen

    19 shared publications
  • Jens Faber

    Department of Endocrinology-Internal Medicine, Copenhagen University Hospital, Herlev-Gentofte Hospital; Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

    8 shared publications
  • Morten Schou

    Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; Department of Cardiology, Copenhagen University Hospital, Herlev-Gentofte Hospital, Denmark

    8 shared publications
  • Christian Selmer

    Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark

    5 shared publications
  • Dirk L. Christensen

    Medical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, United Kingdom; Department of Public Health, University of Copenhagen, Copenhagen, Denmark

    5 shared publications
  • Finn Gustafsson

    Department of Cardiology Rigshospitalet Copenhagen Denmark

    5 shared publications

Latest Publications

  • Characterization of Leydig Cell Dysfunction in Previous Illicit Androgen Users

    by Yeliz Bulut, Niels Brandt-Jacobsen, Rasmus Madsen, Mario Thevis, Jan Frystyk, Jakob Albrethsen, Niels Jørgensen, Anders Juul, Caroline Kistorp, Jon Jarløv Rasmussen

    Background and Objectives: A few studies have explored the impairment of pituitary gonadotroph and Leydig cell function in men who recently ceased illicit androgen use, as assessed by stimulation tests. However, the capacity of the pituitary-testis axis in previous users who discontinued androgen use years ago remains unclear. This study evaluated the pituitary-testis-axis capacity in previous illicit androgen users and nonusers. Methods: We conducted a cross-sectional study of recreational strength training men with (n = 30) and without (n = 26) a history of illicit androgen use. Previous users were subdivided into 2 subgroups based on detectable (group 1, n = 17) and undetectable (group 2, n = 13) performance-enhancing drugs in the urine. We performed gonadotropin-releasing hormone and human chorionic gonadotropin (hCG) stimulation tests. Serum LH was measured with immunoassay, total testosterone, and insulin-like factor 3 with liquid chromatography-tandem mass spectrometry. Sexual function was assessed using the 15-question International Index of Erectile Function questionnaire. Results: Elapsed duration since androgen cessation, geometric mean (95% confidence interval), was 1.9 (1.2; 3.0) years in previous androgen users. The mean (SD) age of all participants was 33 (8) years. Testosterone secretion after hCG injection was lower in previous users than nonusers: group 1 difference, −6.4 (−11.3; −1.5) nmol/L, (P = .031); group 2 difference, −14.2 (−19.5; −8.8) nmol/L, (P < .001). LH secretion did not differ between the groups. Multivariate linear regressions using erectile function as a dependent variable revealed that higher testosterone secretion during the hCG test (P = .046) was independently associated with better erectile function, whereas baseline serum testosterone (P = .780) and estradiol (P = .405) were not. Conclusion: Previous illicit androgen users exhibited decreased Leydig cell capacity 2 years after androgen cessation, which potentially influences erectile function.


  • Response to Letter to the Editor From van Os et al: “Persistently Decreased Quality of Life and its Determinants in Previous Illicit Androgen Users”

    by Yeliz Bulut, Caroline Kistorp, Jon Jarløv Rasmussen

    Yeliz Bulut, Caroline Kistorp, Jon Jarløv Rasmussen; Response to Letter to the Editor from van Os et al.:“Persistently Decreased Quality of Life and its De

  • Persistently Decreased Quality of Life and its Determinants in Previous Illicit Androgen Users

    by Yeliz Bulut, Niels Brandt-Jacobsen, Laust Buhl, Morten Schou, Jan Frystyk, Caroline Kistorp, Jon Jarløv Rasmussen

    Background and objective Quality of life (QoL) has never been assessed in previous illicit users of androgens years following androgen cessation. Therefore, the objective of this study was to assess QoL in previous illicit androgen users compared with current illicit androgen users and controls who had never used androgens. Methods Cross-sectional study including men involved in recreational strength training grouped according to their history of androgen use. We used the RAND Short-Form (SF)-36 questionnaire to assess physical and mental health-related QoL. Results We included 77 previous and 118 current androgen users and 39 healthy nonusers. The mean (SD) age of all participants was 33 (8) years. The elapsed duration since androgen cessation, geometric mean (95% CI), was 2.0 (1.5; 2.6) years in former users. Median (25th-75th percentiles) serum total testosterone was lower in former users than controls, 14 (11-17) versus 19 (16-21) nmol/L, P<0.001. Previous users displayed lower mean (SD) across both mental (MCS) and physical (PCS) component summary scores, 48 (10) versus 54 (4) (P=0.004) and 48 (9) versus 53 (3) (P=0.002) compared with controls. Using multivariate linear regressions, evaluating PCS and MCS as dependent variables, lower serum total testosterone, longer duration since androgen cessation, study recruitment from an endocrine outpatient clinic and established chronic diseases were all independently associated with reduced QoL in previous users, P<0.05. Conclusions Previous illicit androgen users exhibited reduced QoL two years after androgen discontinuation, which may be a persistent condition.


  • Higher Myonuclei Density in Muscle Fibers Persists Among Former Users of Anabolic Androgenic Steroids

    by Jakob Lindberg Nielsen, Jon Jarløv Rasmussen, Mikkel Nicklas Frandsen, Jeppe Fredberg, Niels Høegh Brandt-Jacobsen, Per Aagaard, Caroline Kistorp

    Background and objective No information exists on the long-lasting effects of supraphysiological anabolic androgenic steroids (AAS) usage on the myocellular properties of human skeletal muscle in previous AAS users. We hypothesized former AAS users would demonstrate smaller myonuclei domains (i.e., higher myonuclei density) compared to matched controls. Methods A community-based cross-sectional study in men aged 18-50 years engaged in recreational strength training. Muscle biopsies were obtained from the m. vastus lateralis. Immunofluorescence analyses were performed to quantify myonuclei density and myofiber size. Results Twenty-five males were included: 8 current and 7 previous AAS users and 10 controls. Median (25th-75th percentiles) accumulated duration of AAS use was 174 (101–206) and 140 (24–260) weeks in current and former AAS users, respectively (P = 0.482). Geometric mean (95%CI) elapsed duration since AAS cessation was 4.0 (1.2; 12.7) years among former AAS users. Type II muscle fibers in former AAS users displayed higher myonuclei density and DNA-to-cytoplasm ratio than controls, corresponding to smaller myonuclei domains (P = 0.013). Longer accumulated AAS use (weeks, log2) was associated with smaller myonuclei domains in previous AAS users, beta-coefficient (95%CI), -94 (-169; -18), P = 0.024. Type I fibers in current AAS users exhibited a higher amount of satellite cells per myofiber (P = 0.031) compared to controls. Conclusion Muscle fibers in former AAS users demonstrated persistently higher myonuclei density and DNA-to-cytoplasm ratio four years after AAS cessation suggestive of enhanced retraining capacity.


  • Effect of high-dose mineralocorticoid receptor antagonist eplerenone on urinary albumin excretion in patients with type 2 diabetes and high cardiovascular risk: Data from the MIRAD trial

    by Niels H. Brandt-Jacobsen, Marie Louise Johansen, Jon Rasmussen, Julie L. Forman, Maria Refsgaard Holm, Jens Faber, Patrick Rossignol, Morten Schou, Caroline Kistorp


  • An Abductive Inference Approach to Assess the Performance-Enhancing Effects of Drugs Included on the World Anti-Doping Agency Prohibited List

    by Andreas Breenfeldt Andersen, Glenn A. Jacobson, Jacob Bejder, Dino Premilovac, Stephen M. Richards, Jon J. Rasmussen, Søren Jessen, Morten Hostrup

    Some have questioned the evidence for performance-enhancing effects of several substances included on the World Anti-Doping Agency’s Prohibited List due to the divergent or inconclusive findings in randomized controlled trials (RCTs). However, inductive statistical inference based on RCTs-only may result in biased conclusions because of the scarcity of studies, inter-study heterogeneity, too few outcome events, or insufficient power. An abductive inference approach, where the body of evidence is evaluated beyond considerations of statistical significance, may serve as a tool to assess the plausibility of performance-enhancing effects of substances by also considering observations and facts not solely obtained from RCTs. Herein, we explored the applicability of an abductive inference approach as a tool to assess the performance-enhancing effects of substances included on the Prohibited List. We applied an abductive inference approach to make inferences on debated issues pertaining to the ergogenic effects of recombinant human erythropoietin (rHuEPO), beta2-agonists and anabolic androgenic steroids (AAS), and extended the approach to more controversial drug classes where RCTs are limited. We report that an abductive inference approach is a useful tool to assess the ergogenic effect of substances included on the Prohibited List—particularly for substances where inductive inference is inconclusive. Specifically, a systematic abductive inference approach can aid researchers in assessing the effects of doping substances, either by leading to suggestions of causal relationships or identifying the need for additional research.


  • Open Access

    Serum Insulin-like Factor 3 Levels Are Reduced in Former Androgen Users, Suggesting Impaired Leydig Cell Capacity

    by Jon Jarløv Rasmussen, Jakob Albrethsen, Mikkel Nicklas Frandsen, Niels Jørgensen, Anders Juul, Caroline Kistorp

    Context Illicit use of anabolic androgenic steroids (AAS) is frequently observed in men and is associated with subsequent testosterone deficiency although the long-term effect on gonadal function is still unclear. Serum insulin-like factor 3 (INSL3) has been suggested to be a superior biomarker of Leydig cell secretory capacity compared to testosterone. Objective This study aimed to investigate serum INSL3 concentrations in AAS users. Methods This community-based, cross-sectional study included men aged 18 to 50 years, involved in recreational strength training and allocated to 1 of 3 groups: never-AAS users as controls (n = 44), current (n = 46), or former AAS users (n = 42) with an average duration since AAS cessation of 32 (23 ; 45) months. Results Serum INSL3 was lower in current AAS users and former AAS users than in controls, median (interquartile range), 0.04 µg/L (nondetectable [ND]-0.07 µg/L) and 0.39 µg/L (0.24-0.62 µg/L) vs 0.59 µg/L (0.45-0.72 µg/L), P less than .001. Former AAS users exhibited lower serum INSL3 levels than controls in a multivariable linear regression even after adjusting for serum total testosterone (TT) and other relevant confounders, (B) (95% CI), –0.16 µg/L (95% CI, –0.29 to –0.04 µg/L), P equal to .011. INSL3 and TT were not associated in the model, P equal to .821. Longer accumulated AAS duration (log2) was associated with lower serum INSL3 in former AAS users, (B) (95% CI), –0.08 (95% CI, –0.14 to –0.01), P equal to .022. Serum INSL3, but not inhibin B or testosterone, was associated with testicular size in a multivariate linear regression, (B) (95% CI); 4.7 (95% CI, 0.5 to 8.9), P equal to .030. Conclusion Serum INSL3 is reduced years following AAS cessation in men, independently of testosterone, suggesting persistently impaired Leydig cell capacity.


  • The impact of the glucagon‐like peptide‐1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes

    by Roni Nielsen, Anders Jorsal, Rasmus Stilling Tougaard, Jon Jarløv Rasmussen, Morten Schou, Lars Videbæk, Ida Gustafsson, Jens Faber, Allan Flyvbjerg, Henrik Wiggers, et al.

    Aim: To assess the effect of liraglutide, a glucagon‐like peptide‐1 receptor agonist, on urinary sodium excretion as well as on circulating adrenomedullin and copeptin levels in patients with type 2 diabetes (T2D). Materials and methods: In the LIVE study, patients (n = 241) with left ventricular ejection fraction ≤45% were randomized to liraglutide 1.8 mg daily or placebo for 24 weeks, and 30% had a concomitant diagnosis of T2D. Plasma levels of N‐terminal brain‐natriuretic‐peptide (NT‐proBNP) (a predefined secondary endpoint), midregional pro‐atrial‐natriuretic‐peptide (MR‐proANP), midregional pro‐adrenomedullin (MR‐proADM) and copeptin were measured at baseline and after 24 weeks in this substudy. The potential effect modification of T2D was assessed. Results: In the eligible subgroup of 231 patients with available biomarkers (115 randomized to liraglutide and 116 to placebo), MR‐proANP decreased by 12% ( P = .002) and NT‐proBNP by 9% ( P = .009) during liraglutide treatment compared with placebo at week 24. Interaction with T2D for the treatment effect of change in MR‐proANP and NT‐proBNP levels was P = .003 and P = .03, respectively. Consequently, in patients with T2D, liraglutide decreased MR‐proANP by 27% ( P < .001) and NT‐proBNP by 25% ( P = .02) compared with placebo, whereas no change was observed in patients without T2D. There was no effect of liraglutide on MR‐proADM ( P = .10) or copeptin ( P = .52). Conclusion: Liraglutide decreased the A‐ and B‐type natriuretic peptides significantly in patients with heart failure with reduced ejection fraction (HFrEF) and concomitant T2D, suggesting a beneficial mechanism of liraglutide in T2D patients with HFrEF.


  • Letter to the Editor: “Rate and Extent of Recovery from Reproductive and Cardiac Dysfunction Due to Androgen Abuse in Men”

    by Jon J Rasmussen, Caroline Kistorp

    Illicit use of anabolic androgenic steroids (AASs) among men has become a public health concern, although, until recently, knowledge on the side-effects were li


  • Open Access

    Endogenous Testosterone Levels Are Associated with Risk of Type 2 Diabetes in Women without Established Comorbidity

    by Jon J Rasmussen, Christian Selmer, Signe Frøssing, Morten Schou, Jens Faber, Christian Torp-Pedersen, Gunnar H Gislason, Lars Køber, David M Hougaard, Arieh S Cohen, et al.

    Purpose: The impact of endogenous androgen levels on the risk of type 2 diabetes in women remains uncertain. The objective was to investigate associations between endogenous androgen levels and risk of type 2 diabetes in young women without established comorbidity. Methods: In this retrospective cohort study, women aged 18 to 50 years who underwent measurement of plasma testosterone, dehydroepiandrosterone-sulfate (DHEA-S), dihydrotestosterone (DHT), and sex hormone-binding globulin (SHBG) for the first time from January 2007 to December 2015 were included. Androgens were analyzed using tandem liquid chromatography mass spectrometry. Women with established comorbidity were excluded, using Danish healthcare registries. We calculated incidence rate ratios (IRRs, 95% confidence intervals) of type 2 diabetes according to quartiles of plasma androgens using multivariate Poisson regression models. Results: A total of 8876 women, with a mean ± SD age of 38.5 ± 4.6 years and a median (interquartile range [IQR]) follow-up duration of 8.1 (6.6-9.4) years, were eligible for analyses. During 69 728 person-years, 69 women were diagnosed with type 2 diabetes. Women in the highest quartile of plasma total testosterone and calculated free testosterone displayed increased risk of type 2 diabetes compared with the lowest quartile: IRR 1.97 (1.01; 3.85), P = .048 and IRR 7.32 (2.84; 18.83), P < .001. SHBG was inversely associated with type 2 diabetes, Q4 versus Q1; IRR 0.06 (0.02; 0.21), P < .001. Plasma DHEA-S and DHT were not associated with incident type 2 diabetes. Conclusions: Higher levels of plasma total and free testosterone were associated with increased risk of type 2 diabetes among women.